- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02322099
Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss (APART)
A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy
Antiretroviral therapy (ART) initiation is associated with a significant loss of bone mineral density (BMD), characterised by increases in bone turnover, which is largely limited to the first 48 weeks of therapy. Bisphosphonates, such as alendronate, decrease bone turnover and can limit loss of bone mineral density.
This study aims to determine if a short course of treatment with the oral bisphosphonate alendronate can limit loss of bone mineral density associated with initiation of ART in HIV-1 infected, antiretroviral naive, adult subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multi-centre, prospective, randomised, double-blind, placebo-controlled trial over 50 weeks. The aims of this study include:
- To determine if short-course treatment with alendronate versus placebo combined with calcium and vitamin D, initiated 2 weeks prior to start of ART and can prevent loss of BMD over 48 weeks of follow-up post ART initiation.
- To explore the effect of alendronate on bone turnover in the setting of ART initiation.
- To determine which factors, such as choice of ART, impacts the protective effect of alendronate in preventing BMD loss.
- To determine the relationship between changes in bone turnover markers, vitamin D, parathyroid hormone and calcium levels.
- To explore the pathogenesis of BMD loss with initiation of ART by investigating relationships between changes in immune function (T-cells and B-cells subsets), bone turnover and BMD.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Dublin, Ireland, 9
- Beaumont Hospital
-
Dublin, Ireland, 7
- Mater Misericordiae University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male>30 years old or female>35 years old
- HIV-1 antibody positive
- antiretroviral therapy naïve
- be presumed to have achieved peak bone mass
- be eligible for initiation of antiretroviral therapy in the opinion of the investigator
- be able to provide written, informed consent
Exclusion Criteria:
- subjects unable to comply with the study protocol or unable to stand/sit upright for at least 30 minutes
- history of osteoporosis
- history of fragility fracture or previous femoral fracture
- chronic renal failure
- hypocalcemia or hypercalcemia at screening
- history of Paget's disease or known primary hyperparathyroidism
- previous treatment with or allergy (including hypersensitivity) to bisphosphonates
- recent history (past 12 months) of peptic or duodenal ulcers or oesophagitis, aspiration or any other abnormality of the oesophagus
- current therapy with prescribed calcium or vitamin D preparations (other than over-the-counter multivitamin preparations)
- current therapy with aspirin or other regularly prescribed non-steroidal anti-inflammatory drugs
- recent dental work (within the past 3 months) or poor oral hygiene (as judged in the opinion of the investigator)
- recent (within the past three months) significant steroid exposure
- for female subjects: pregnancy at screening, planning future pregnancies or unwilling to take measures to avoid pregnancy for the duration of the study
- where in the investigator's opinion, there is a necessity to initiate ART within the pre-ART study window period
- hepatitis B or hepatitis C co-infection
- any active illness (including AIDS illness) which in the opinion of the investigator precludes participation in the study
- subjects concurrently enrolled in another clinical trial of an investigational medical product
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Alendronate
Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
|
alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
Other Names:
Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
Other Names:
Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
Other Names:
|
Placebo Comparator: Placebo
Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
|
Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
Other Names:
Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
Other Names:
Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of changes in bone mineral density
Time Frame: 50 weeks
|
Between-group differences in percentage change in total hip, lumbar spine, femoral neck BMD and body composition to week 50 among subjects who received at least one dose of the study medication
|
50 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of changes in bone turnover markers
Time Frame: 50 weeks
|
Between-group differences in percentage change in bone turnover markers
|
50 weeks
|
Impact of ART choice on alendronate protective effect
Time Frame: 50 weeks
|
Impact of choice of ART on changes in BMD and bone turnover markers
|
50 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathogenesis of BMD loss with initiation of ART
Time Frame: 50 weeks
|
Relationship between changes in T-cell and B-cell subsets, bone turnover and BMD with ART initiation
|
50 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Patrick WG Mallon, MB BCh BAO,PhD,FRCPI, University College Dublin
Publications and helpful links
General Publications
- Cotter AG, Sabin CA, Simelane S, Macken A, Kavanagh E, Brady JJ, McCarthy G, Compston J, Mallon PW; HIV UPBEAT Study Group. Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS. 2014 Sep 10;28(14):2051-60. doi: 10.1097/QAD.0000000000000353.
- McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007 Nov 30;21(18):2473-82. doi: 10.1097/QAD.0b013e3282ef961d.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Bone Demineralization, Pathologic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Gastrointestinal Agents
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Antacids
- Tenofovir
- Vitamin D
- Cholecalciferol
- Calcium
- Alendronate
- Calcium Carbonate
Other Study ID Numbers
- APART_2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Demineralization
-
Nantes University HospitalTerminatedBone Demineralization Lesions in the Injured MarrowFrance
-
PfizerActive, not recruitingMenopause | Bone DemineralizationKorea, Republic of
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHypoestrogenism | Bone Demineralization | Subclinical Kidney Injury | Bone MicroarchitectureUganda
-
Shriners Hospitals for ChildrenCompletedBurns | Bone DemineralizationUnited States
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustCompletedSleep Disturbance | Muscle Atrophy | Weightlessness | Astronaut-Bone Demineralisation SyndromeUnited Kingdom
-
Rambam Health Care CampusUnknownPeriodontitis | Dental Caries | Alveolar Bone Losses
-
University of Colorado, DenverCompletedDemineralizationUnited States
-
Cairo UniversityUnknownDemineralization, Tooth | Demineralization, Fissure | Non-Cavitated Caries
-
The University of Hong KongUnknownWhite Spot Lesion | Caries,Dental | Demineralization, ToothHong Kong
-
Hacettepe UniversityCompletedTooth DemineralizationTurkey
Clinical Trials on Alendronate
-
University of California, DavisNational Heart, Lung, and Blood Institute (NHLBI); Doris Duke Charitable FoundationNot yet recruitingOsteonecrosis | Avascular Necrosis | Sickle Cell Disease | Sickle Cell Anemia | Ischemic Necrosis
-
Aarhus University HospitalCompleted
-
Shanghai JMT-Bio Inc.Not yet recruitingGlucocorticoid Induced OsteoporosisChina
-
Göteborg UniversityCompletedOsteoporosis | Ankylosing SpondylitisSweden
-
National Institute of Diabetes and Digestive and...CompletedProstate Cancer | Osteoporosis | HypogonadismUnited States
-
National Taiwan University HospitalCompletedOsteoporosis | End-Stage Renal Disease
-
Chinese University of Hong KongRecruitingACL ReconstructionHong Kong
-
Aarhus University HospitalUniversity of AarhusCompleted
-
National Institute of Dental and Craniofacial Research...CompletedPolyostotic Fibrous DysplasiaUnited States
-
Ciudad Universitaria, SpainCompleted